SCHEMBL6310816

SCHEMBL6310816

CCCCc1c(C)c(C#N)c2nc3c(C)cccn3c2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.46
NPSR1 Q6W5P4 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 3/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 6/20 0.40
CASP7 P55210 4/20 0.40
HSD17B10 Q99714 4/20 0.40
CASP1 P29466 3/20 0.40
MEN1 O00255 1/20 0.38
KDM4E B2RXH2 7/20 0.37
GAA P10253 4/20 0.37
LMNA P02545 3/20 0.37
APAF1 O14727 1/20 0.37
NOD2 Q9HC29 1/20 0.37
SLC2A1 P11166 1/20 0.37
NPC1 O15118 1/20 0.36
MDM2 Q00987 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312086 0.83 MAPT (0.47) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6311562 0.80 HPGD (0.43) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6310742 0.80 HPGD (0.43) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6311045 0.78 KMT2A (0.43) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6313605 0.75 NPSR1 (0.40) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6310328 0.73 NPSR1 (0.44) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6319304 0.72 SMN1; SMN2 (0.43) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6310807 0.70 KMT2A (0.72) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6312327 0.70 SMN1; SMN2 (0.39) HPGDNPSR1SMN1; SMN2MAPTKMT2A
SCHEMBL6310471 0.69 HSD17B10 (0.39) HPGDNPSR1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 HPGD 2061/4885NPSR1 1531/4885SMN1; SMN2 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.